Tag: OCD treatment

  • Hoarding Disorder: A Looming National Crisis?

    Hoarding Disorder: A Looming National Crisis?

    A recent article on Medscape, Hoarding Disorder: A Looming National Crisis?, highlights the growing prevalence of hoarding disorder (HD) among older adults. While HD affects approximately 2% of the general population, studies suggest that prevalence may reach up to 6% among individuals over 70 years old.

    HD is characterized by persistent difficulty discarding possessions, even those with little to no monetary value. For individuals with HD, these items often provide a sense of security or serve as emotional reminders of the past. To outsiders, it’s difficult to understand why these possessions hold such deep significance, but for the person with HD, the items have profound sentimental value.

    Hoarding disorder is sometimes viewed as a subset of obsessive-compulsive disorder (OCD), but the overlap is not absolute. Many individuals with HD do not meet diagnostic criteria for OCD and often fail to respond to traditional OCD treatments. In my practice, I’ve come to conceptualize HD less as an extension of OCD and more as a personality-related condition influenced by environmental and psychological factors. For instance, many individuals with HD grew up in homes where similar behaviors were modeled. However, the precise causes of HD remain unclear.

    The consequences of HD are particularly concerning in older adults. The accumulation of clutter can pose significant safety risks, including fire hazards, tripping injuries, and even the potential for homelessness. These dangers were evident in a recent consult case where a medical team sought a psychiatric assessment of an elderly patient living in a severely cluttered home. Although the risks were undeniable, the individual did not meet criteria for psychiatric hospitalization. Even if hospitalization were an option, there is no FDA-approved treatment for HD at this time.

    The most evidence-based intervention we have for HD is cognitive-behavioral therapy (CBT), which requires sustained engagement over many weeks. Unfortunately, a key barrier is that many individuals with HD do not recognize the need for change or are reluctant to participate in therapy. This makes HD a uniquely challenging condition to address.

    Effective management of HD begins with education—helping patients understand the disorder, its risks, and the available treatment options. But education alone is not enough. We urgently need robust community support systems, including services to assist with clearing hazardous clutter and providing ongoing support to encourage treatment adherence.

    Inpatient psychiatric hospitalization, in my opinion, offers little benefit for HD. Instead, we need long-term, community-focused solutions. While policymakers often call for greater action to address mental health challenges, they frequently overlook the resource constraints faced by frontline providers. If we are to rise to this challenge, funding and systemic support must match the urgency of their rhetoric.

    HD is more than a personal struggle—it’s a public health issue with profound implications for individuals, families, and communities. As healthcare providers, we are ready to do more. Now, we need our leaders to step up and provide the resources to make that possible.

  • Ondansetron as an Augmentative Treatment for OCD: What Does the Evidence Say?

    Ondansetron as an Augmentative Treatment for OCD: What Does the Evidence Say?

    Obsessive-Compulsive Disorder (OCD) is often treated with selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT). Despite these interventions, many patients experience only partial relief. This has led researchers to explore augmentation strategies, including the addition of ondansetron, a serotonin 5-HT3 receptor antagonist.

    Mechanism of Action

    • 5-HT3 antagonism: Ondansetron modulates serotonin in a different way compared to SSRIs. Preclinical studies suggest it may reduce compulsive behaviors by altering serotoninergic and dopaminergic activity in brain regions implicated in OCD, such as the orbitofrontal cortex and basal ganglia.

    Evidence from Clinical Trials

    1. Shavakhi et al. (2014):
      • Design: Double-blind, randomized controlled trial (RCT).
      • Participants: 40 patients with OCD who had a partial response to fluoxetine.
      • Intervention: Fluoxetine (20–40 mg/day) + placebo vs. fluoxetine + ondansetron (4 mg/day).
      • Results: Significant improvement in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores with ondansetron by week 8.
      • Conclusion: Ondansetron was well-tolerated and effective as an adjunctive treatment.
    2. Haghighi et al. (2013):
      • Design: Similar double-blind RCT with 60 patients on fluvoxamine (100–200 mg/day).
      • Results: Patients receiving ondansetron (4 mg/day) showed greater reductions in Y-BOCS scores than those on placebo.
      • Conclusion: Ondansetron enhanced the anti-obsessional effects of SSRIs.
    3. Meta-Analysis (Emerging Data):
      • While limited RCTs exist, early analyses highlight ondansetron’s promise, particularly in SSRI partial responders.

    Practical Considerations

    • Dosage: Typically 4 mg/day in studies.
    • Tolerability: Generally well-tolerated, with mild side effects like headache and dizziness reported in trials.
    • Population: Evidence supports its use in patients with partial response to SSRIs.

    Current Limitations

  • Sample Sizes: Studies to date have small cohorts, limiting generalizability.
  • Duration: Most trials span 8–12 weeks, leaving long-term efficacy unclear.
  • Mechanistic Data: While promising, the precise mechanisms remain speculative.
  • Clinical Takeaway

    Ondansetron appears to be a safe and potentially effective augmentation strategy for patients with OCD who have not achieved full remission on SSRIs alone. While more robust data are needed, its unique mechanism and tolerability make it an intriguing option in treatment-resistant cases.